Vericel Corporation (NASDAQ:VCEL) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

• Vericel Corporation (NASDAQ:VCEL) has an average rating of "Moderate Buy" from six brokerages, with four buy recommendations, one hold, and one sell.
• The company's average 12-month price target is $60.40, with recent analyst reports adjusting price targets between $58.00 and $67.00.
• Vericel reported a 20.1% increase in revenue to $63.24 million for the previous quarter, surpassing expectations, while achieving an EPS of ($0.01).

Shares of Vericel Corporation (NASDAQ:VCEL - Get Free Report) have earned an average rating of "Moderate Buy" from the six brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $60.40.

VCEL has been the topic of a number of research analyst reports. Canaccord Genuity Group dropped their price target on Vericel from $61.00 to $58.00 and set a "buy" rating on the stock in a research report on Friday, August 1st. Stephens restated an "overweight" rating and set a $67.00 target price on shares of Vericel in a report on Monday, June 16th. BTIG Research downgraded shares of Vericel from a "buy" rating to a "neutral" rating in a report on Wednesday, September 17th. Finally, Weiss Ratings restated a "sell (d+)" rating on shares of Vericel in a report on Wednesday.

Institutional Trading of Vericel

Several hedge funds and other institutional investors have recently modified their holdings of the company. Corient Private Wealth LLC bought a new stake in shares of Vericel in the second quarter valued at about $282,000. Valeo Financial Advisors LLC raised its position in Vericel by 11.1% in the 2nd quarter. Valeo Financial Advisors LLC now owns 10,300 shares of the biotechnology company's stock valued at $438,000 after buying an additional 1,026 shares during the last quarter. Osaic Holdings Inc. raised its position in Vericel by 13.7% in the 2nd quarter. Osaic Holdings Inc. now owns 2,937 shares of the biotechnology company's stock valued at $125,000 after buying an additional 353 shares during the last quarter. Public Sector Pension Investment Board raised its position in Vericel by 9.7% in the 2nd quarter. Public Sector Pension Investment Board now owns 171,642 shares of the biotechnology company's stock valued at $7,303,000 after buying an additional 15,153 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Vericel by 7,627.4% in the second quarter. Tower Research Capital LLC TRC now owns 4,791 shares of the biotechnology company's stock valued at $204,000 after purchasing an additional 4,729 shares during the last quarter.

Vericel Stock Performance

VCEL opened at $32.77 on Friday. The firm's fifty day moving average is $34.00 and its two-hundred day moving average is $38.77. The firm has a market cap of $1.65 billion, a PE ratio of 273.11 and a beta of 1.39. Vericel has a twelve month low of $29.24 and a twelve month high of $63.00.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.03. The business had revenue of $63.24 million for the quarter, compared to the consensus estimate of $64.61 million. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The firm's revenue was up 20.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.10) EPS. Equities analysts forecast that Vericel will post 0.14 EPS for the current fiscal year.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.